Assurance in vaccine efficacy clinical trial design based on immunological responses

por Callegaro, Andrea, Zahaf, Toufik, Tibaldi, Fabian
Publicado 2021

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults

por Lal, Himal, Zahaf, Toufik, Heineman, Thomas C.
Publicado 2013

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis...

por Dagnew, Alemnew F, Rausch, Debora, Hervé, Caroline, Zahaf, Toufik, Levin, Myron J, Schuind, Anne
Publicado 2020

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine

por Callegaro, Andrea, Burny, Wivine, Hervé, Caroline, Hyung Kim, Joon, Levin, Myron J, Zahaf, Toufik, Cunningham, Anthony L, Didierlaurent, Arnaud M
Publicado 2021

26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis

por Callegaro, Andrea, Willer, David O, Burny, Wivine, Hervé, Caroline, Kim, Joon Hyung, levin, myron J, Zahaf, Toufik, Cunningham, Anthony L, Didierlaurent, Arnaud
Publicado 2021

2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Hyung Kim, Joon, Levin, Myron J, Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L
Publicado 2019

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

por Colindres, Romulo, Wascotte, Valentine, Brecx, Alain, Clarke, Christopher, Hervé, Caroline, Kim, Joon Hyung, Levin, Myron J., Oostvogels, Lidia, Zahaf, Toufik, Schuind, Anne, Cunningham, Anthony L.
Publicado 2020

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination

por Naud, Paulo S, Roteli-Martins, Cecilia M, De Carvalho, Newton S, Teixeira, Julio C, de Borba, Paola C, Sanchez, Nervo, Zahaf, Toufik, Catteau, Gregory, Geeraerts, Brecht, Descamps, Dominique
Publicado 2014

2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis

por Willer, David O, Wascotte, Valentine, Kim, Joon Hyung, Zahaf, Toufik, Talarico, Carla, Gorfinkel, Iris, Gervais, Pierre, Pharm, Pharm, L, Cunningham, Anthony L, Oostvogels, Lidia, Colindres, Romulo, Schuind, Anne
Publicado 2019

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

por Kim, Joon Hyung, Diaz-Decaro, John, Jiang, Ning, Hwang, Shinn-Jang, Choo, Eun Ju, Co, Maribel, Hastie, Andrew, Hui, David Shu Cheong, Irimajiri, Junya, Lee, Jacob, Leung, Edward Man-Fuk, Tang, Haiwen, Tsuru, Tomomi, Watson, Philip, Wu, Zhenhua, Yu, Chong-Jen, Yuan, Yanfei, Zahaf, Toufik, Cunningham, Anthony L., Schuind, Anne
Publicado 2021

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

por Oostvogels, Lidia, Heineman, Thomas C., Johnson, Robert W., Levin, Myron J., McElhaney, Janet E., Van den Steen, Peter, Zahaf, Toufik, Dagnew, Alemnew F., Chlibek, Roman, Diez-Domingo, Javier, Gorfinkel, Iris S., Hervé, Caroline, Hwang, Shinn-Jang, Ikematsu, Hideyuki, Kalema, George, Lal, Himal, McNeil, Shelly A., Mrkvan, Tomas, Pauksens, Karlis, Smetana, Jan, Watanabe, Daisuke, Weckx, Lily Yin, Cunningham, Anthony L.
Publicado 2019

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 an...

por Boutry, Céline, Hastie, Andrew, Diez-Domingo, Javier, Tinoco, Juan Carlos, Yu, Chong-Jen, Andrews, Charles, Beytout, Jean, Caso, Covadonga, Cheng, Huey-Shinn, Cheong, Hee Jin, Choo, Eun Ju, Curiac, Dan, Di Paolo, Emmanuel, Dionne, Marc, Eckermann, Tamara, Esen, Meral, Ferguson, Murdo, Ghesquiere, Wayne, Hwang, Shinn-Jang, Avelino-Silva, Thiago Junqueira, Kosina, Pavel, Liu, Chiu-Shong, Markkula, Jukka, Moeckesch, Beate, Murta de Oliveira, Cláudia, Park, Dae Won, Pauksens, Karlis, Pirrotta, Paola, Plassmann, Georg, Pretswell, Carol, Rombo, Lars, Salaun, Bruno, Sanmartin Berglund, Johan, Schenkenberger, Isabelle, Schwarz, Tino, Shi, Meng, Ukkonen, Benita, Zahaf, Toufik, Zerbini, Cristiano, Schuind, Anne, Cunningham, Anthony L
Publicado 2021